Table 1.
Study characteristics
| Variable | Frequency | Percent (%) |
| Year of publication | ||
| 2007–2009 | 70 | 24 |
| 2010–2012 | 45 | 16 |
| 2013–2015 | 73 | 25 |
| 2016–2018 | 72 | 25 |
| 2019–2020 | 29 | 10 |
| Country | ||
| USA | 143 | 49 |
| UK | 33 | 11 |
| Canada | 19 | 7 |
| Australia | 12 | 4 |
| France | 6 | 2 |
| Germany | 5 | 2 |
| N/A | 62 | 21 |
| Study type | ||
| N/A | 130 | 45 |
| Qualitative | 68 | 24 |
| Quantitative | 68 | 24 |
| Mixed methods | 23 | 8 |
| Study design/Manuscript type | ||
| Editorial/Commentary | 89 | 31 |
| Other | 28 | 10 |
| Systematic review | 27 | 9 |
| Surveys | 24 | 8 |
| Other literature review | 20 | 7 |
| Observational | 19 | 7 |
| Randomized controlled trial | 19 | 7 |
| Other type of review/report | 15 | 5 |
| Interviews (structured or semi-structured) | 13 | 4 |
| Multiple designs | 10 | 3 |
| Case report | 8 | 3 |
| Case series | 7 | 2 |
| Policy statement | 6 | 2 |
| Non-randomized experimental study | 1 | 0 |
| Scoping review | 1 | 0 |
| Meta-analysis | 1 | 0 |
| Case-control study | 1 | 0 |
| Trauma/Emergency specific | 263 | 91 |
| Disparities in study enrollment addressed | 26 | 9 |
| Pediatric focused | 42 | 15 |
| Geriatric focused | 4 | 1 |
| Outbreak related | 26 | 9 |
| COVID-19 related | 3 | 1 |
| Regulatory body discussed | ||
| US Food and Drug Administration (FDA) | 119 | 41 |
| US Department of Health and Human Services (HHS) | 42 | 15 |
| EU/European Commission | 8 | 3 |
| Department of Defense (DoD) | 9 | 3 |
| National Institutes of Health (NIH) | 12 | 4 |
| Special populations included or addressed | ||
| Children | 52 | 18 |
| Prisoners | 3 | 1 |
| Pregnant women | 13 | 4 |
| Mentally disabled persons | 3 | 1 |
| Economically/Educationally disadvantaged | 9 | 3 |
| Students | 8 | 3 |
| Victims of violence | 19 | 7 |
DoD, Department of Defense; EU, European Union; FDA, Food and Drug Administration; N/A, not available; NIH, National Institutes of Health.